Base-Editing Therapy Shows Durable Efficacy in Sickle Cell Disease

Key facts

• CorrectSequence Therapeutics reports 15-month follow-up data for CS-206.
• The base-editing therapy demonstrated durable, VOC-free efficacy.
• The therapy showed a favorable safety profile.
• CorrectSequence Therapeutics is using transformer Base Editing (tBE) technology.

Sickle cell disease is a genetic blood disorder that causes red blood cells to become misshapen, leading to pain, organ damage, and reduced lifespan. Gene therapies, including base editing, offer potential cures by correcting the underlying genetic defect. Positive long-term data from therapies like CS-206 are crucial for demonstrating the viability and safety of these advanced treatments.